John McKearn has been promoted to CEO of Kalypsys, the San Diego-based company said last week.
McKearn joined the company in 2003 as chief scientific officer and became Kalypsys’ president in 2004. Prior to his employment with Kalypsys, he was senior vice president of research at Pharmacia. He has also held senior positions at G.D. Searle, the pharmaceutical subsidiary of Monsanto, Kalypsys said. McKearn holds a PhD in immunology from the University of Chicago and a bachelor’s degree from Northern Illinois University.
The Howard Hughes Medical Institute on last week named 43 new investigators, chosen from almost 300 proposals in a nationwide competition.
Among the new HHMI investigators are microbial microarray pioneer Joe DeRisi, an associate professor of biochemistry at the University of California, San Francisco; RNAi researchers Tom Tuschl, an associate professor at Rockefeller University, and Greg Hannon, a professor at Cold Spring Harbor Laboratory; Evan Eichler, an associate professor of genome sciences at the University of Washington in Seattle; Kevin Shokat, a professor of cellular and molecular pharmacology at the University of California, San Francisco; and Stephen Quake, a professor of bioengineering at Stanford University.